Neurocrine's CRENESSITY Shows Sustained Cardiometabolic Benefits in CAH Patients

Event summary

  • Neurocrine Biosciences presented two-year data from the CAHtalyst Adult study showing sustained improvements in cardiometabolic outcomes for classic congenital adrenal hyperplasia (CAH) patients treated with CRENESSITY (crinecerfont).
  • Among overweight or obese participants, 37% achieved >5% weight reduction, and 43% of those with insulin resistance at baseline were no longer insulin resistant at two years.
  • Bone health outcomes showed favorable trends, including improvements in bone mineral density, particularly in the lumbar spine.
  • Patient-reported outcomes indicated high treatment satisfaction, with 96% of respondents moderately or very satisfied with CRENESSITY.

The big picture

Neurocrine's data underscores the potential of CRENESSITY to redefine CAH management by addressing long-term cardiometabolic risks associated with traditional glucocorticoid treatments. The results position the drug as a key player in the rare disease space, where sustained efficacy and patient-reported outcomes are critical for market success. The findings also highlight the growing emphasis on holistic health improvements beyond immediate symptom control.

What we're watching

Market Adoption
Whether the sustained cardiometabolic benefits will drive broader adoption of CRENESSITY among CAH patients and healthcare providers.
Regulatory Dynamics
How the FDA and other regulators may respond to the long-term data, potentially influencing future approvals or labeling updates.
Competitive Positioning
The pace at which Neurocrine can differentiate CRENESSITY in the CAH treatment landscape, especially against existing glucocorticoid therapies.